Premier Buffer A and B Reagent 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Trinity Biotech 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2017-02-28
  • 사례 출판 날짜
    2017-02-28
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: trinity biotech premier buffer a and b reagent medical device manufacturer, trinity biotech, has issued a medical device safety alert concerning its premier buffer a reagent [product code (lot number): 01-03-0080 (6873, 6669)] and premier buffer b reagent [product code (lot number):: 01-03-0081 (6374), 01-03-0096 (6859, 6639, 6506), 42664 (6528, 6633 and 6526)]. the manufacturer has received reports of difficulty in recovering controls (qc verification), using the above reagent lots, following system activation or standby mode. upon review, the manufacturer has confirmed that the first two test results following system activation or standby mode, with these reagent lots, may result in a low bias, whether they are a control or patient sample. the manufacturer is asking users of the above listed reagent lots for testing to review the following scenarios: if two controls were run directly after activation or standby and met acceptable criteria, there is no action required. if initial controls failed but were re-run and met acceptable criteria, there is no action required. if only patient samples were run directly after activation or standby, then a review of the first two (2) patient sample results is required. affected users should also take the following actions- discontinue the use of the above reagent lots. destroy any remaining product. confirm end-users’ laboratory practice of the use of two controls (qc verification) immediately following system standby and system activations. according to the manufacturer, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 28 february 2017.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Trinity Biotech Premier Buffer A and B Reagent
  • Manufacturer

Manufacturer